Sponsors (2)
The bill makes it easier and cheaper for generics and biosimilars to be approved and marketed—potentially speeding patient access and reducing costs—at the cost of weakening some patent enforcement tools and creating possible long-term impacts on innovation incentives and clarity about approved uses.
Patients with chronic conditions — may gain earlier access to lower-cost generic and biosimilar drugs because manufacturers face lower patent-litigation risk when seeking approval and marketing with approved labeling.
Generic and biosimilar manufacturers (including small-business owners) and hospitals/health systems — can seek FDA approval and market products without facing method-of-use patent suits when they comply with the statute's safe-harbor (statutory statement and avoid promoting patented uses), reducing litigation risk and barriers to entry.
Courts, manufacturers, and health systems — gain clearer legal standards because the statute explicitly defines safe-harbor conditions and key terms (labeling, promoting, commercial marketing), which should reduce uncertainty and litigation over method-of-use claims.
Patent owners and drug innovators — may lose enforcement tools against off-label or method-of-use promotion tied to patents, weakening incentives for certain drug innovations.
Taxpayers, payers, and health insurers — could face longer-term trade-offs if reduced patent enforcement lowers revenues for innovators and shifts R&D investment, potentially affecting future drug development and public spending.
Patients with chronic conditions, clinicians, and hospitals — could experience confusion or safety risks if manufacturers narrowly tailor promotion to avoid liability, increasing uncertainty about which uses are FDA‑approved versus covered by method-of-use patents.
Based on analysis of 2 sections of legislative text.
Creates statutory safe harbors that protect certain generic and biosimilar approval activities, labeling, and ordinary promotion from patent-infringement claims that rely on method-of-use patents, so long as the applicant makes the required FDA statutory statement and the labeling and promotion do not refer to the patented uses. The protection covers abbreviated new drug applications (ANDAs), certain 505(b)(2) and animal drug applications, and biosimilar (351(k)) applications, and includes definitions of key terms; it applies both prospectively and retroactively to pending and past proceedings upon enactment.
Introduced December 5, 2025 by Benjamin Cline · Last progress December 5, 2025